BIO-TECH SYSTEMS, INC.
Market Research in the Health Care Field
4167 W. Pinecrest Circle
Las Vegas, Nevada 89121
(702) 456-7608 (702) 456-2189 FAX
E-Mail:mburns@biotechsystems.com
Web Site: www.biotechsystems.com

NEWS RELEASE

February 1, 2010

FOR IMMEDIATE RELEASE

Contact: Marvin Burns
Tel: (702) 456-7608
Fax: (702) 456-2189

BIO-TECH SYSTEMS ANNOUNCES A NEW RADIOPHARMACEUTICAL REPORT:

Report 310: THE U.S MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS

GOOD PROSPECTS FOR MOST SPECT AND PET RADIOPHARMACEUTICALS, NEW PET PRODUCTS EMERGING FOR CARDIOLOGY AND ONCOLOGY, BIG MARKETS FOR PET AND SPECT NEUROLOGY PRODUCTS FOR ALZHEIMERS'S AND PARKINSON'S, NEW PET MOLECULAR IMAGING PLATFORMS, ANALYSIS AND SALES FORECASTS TO 2017

Bio-Tech Systems Inc. announces the publication of a comprehensive report with detailed analysis of the markets for SPECT and PET radiopharmaceuticals. The report has a strong focus on new products and technology and emerging market opportunities. This covers nuclear cardiology with both PET and SPECT, targeted oncology and new molecular imaging platforms for PET. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease with PET and SPECT. This will broaden the base of nuclear medicine and allow nuclear imaging to compete more effectively in the larger imaging marketplace.

There has been some decline in the number of SPECT myocardial perfusion procedures as well as reduced pricing for Cardiolite and Myoview because of generic sestamibi. The technetium shortage has also added pressure that will continue for the near term. This will encourage more physicians to adopt PET for many cardiology applications as soon as the new perfusion agents are approved. Cardiology PET produces better images and offers higher reimbursement than traditional cardiology SPECT. This will also stimulate the market for rubidium PET. Growth is still expected in cardiology SPECT from specialized products for imaging myocardial infarction and neuronal imbalances in patients that need pacemakers or may be subject to congestive heart failure. These products are in late stage development and will be introduced in the near term.

New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting. This includes new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. This will aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. In the long run, this will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth.

SPECT and PET Radiopharmaceuticals: Market Analysis and Future Prospects

U.S. sales of SPECT and PET radiopharmaceuticals reached $1.16 billion in 2009 and are expected to rise to $4.76 billion by 2017. Total SPECT radiopharmaceutical sales were down 11.6% in 2009 primarily due to reductions in pricing of perfusion agents with the introduction of generic sestamibi. SPECT procedure volume was also down due to the technetium shortage. These pressures will continue in 2010, but eventually stabilize. In comparison, PET procedures were flat compared with the previous year, but revenue was down slightly because of price weakness in the FDG market. However, future sales growth will be more in line with procedure growth.

Although PET reimbursement has been under pressure for the past 2 years, there has been some relief recently. New indications have been approved and reimbursement has improved for certain procedures, particularly in cardiology. Investment in new PET agents is increasing in all segments, which bodes well for this market once the new products are introduced.

Continuing improvements in imaging technology in both SPECT and PET are allowing higher resolution and shorter imaging times. Radiopharmaceutical doses are also going down due to increased imaging efficiency. This makes nuclear medicine safer than many other imaging modalities, which are threatened with excessive radiation and patient safety issues.

As new products are introduced, SPECT sales should more than double during the forecast period from $817 million in 2009 to $1,737 million by 2017. PET sales will increase more rapidly from $348 million in 2009 to $3,028 million by 2017, an increase of more than 700%. This will come primarily from new products as well as increases in the volume of FDG procedures. Market growth will also result from higher prices of the new products. This influx will help all segments of nuclear medicine expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.

ABOUT THE AUTHOR

Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional cardiology and medical imaging, which have been widely distributed. Burns has also served as a consultant to many international firms and venture groups in these fields. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School's advanced management program. He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to forming Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.

SPECT AND PET RADIOPHARMACEUTICALS: REPORT CONTENTS

SECTION I: Market Status, Trends and Forecasts

Analysis of sales trends and opportunities in SPECT and PET markets, competitive challenges, new products in the pipeline and prospects for future growth. Also provides sales forecasts in all product categories to 2017. Products include:

- Nuclear cardiology agents for SPECT and PET. (myocardial perfusion, myocardial viability, neuronal imaging and metabolic imaging). New products include Zemeva for myocardial infarction, Androview for neuronal instability and congestive heart failure, new Lantheus and FluoroPharma PET perfusion and neuronal imaging agents.
- Products for functional SPECT imaging. SPECT and PET neurology imaging including new products for Alzheimer's and Parkinson's imaging from Avid, GE and Bayer.
- Oncology products including ProstaScint, Octreoscan and new products for imaging prostate cancer including Trofex from Molecular Insight. Also, PET apoptosis imaging with Aposense, Cellectar's PLE product and new molecular imaging platforms.

SECTION II: Radiopharmaceutical Products and Technology

- Technical principles and functional characteristics of radiopharmaceutical agents.
- Radioisotope selection and optimization; production methods and trade-offs.
- Challenges in the technetium shortage and options for new sources of molybdenum-99

SECTION III: Clinical Applications

- Discussion of clinical applications for radiopharmaceutical products and technologies.
- Options in radiopharmaceutical selection for both SPECT and PET imaging.
- Analysis of product characteristics, performance benefits and trade-offs.

SECTION IV: Current Developments and Emerging Technologies

- Description of products in development within each major SPECT and PET market segment including cardiology, neurology and oncology.
- Description of new SPECT and PET agents, such as new myocardial imaging agents, angiogenesis imaging for cellular response to therapy, apoptosis imaging and therapy, PLE (phospho-lipid ether) targeting and therapy.

SECTION V: Industry Analysis

- Analysis of current suppliers with individual product sales and market shares in 2009
- Market distribution, pricing strategies and new products in the pipeline.

SECTION VI: End-User Analysis

- Analysis of end-user groups and comparative requirements for medical imaging.
- Procedure mix and product utilization in hospitals and clinics.

SECTION VII: Company Profiles

- Background information on companies in the field and review of recent performance.
- Discussion of each company's market activities and management strategies

LIST OF EXHIBITS—SPECT AND PET RADIOPHARMACEUTICALS

LIST OF EXHIBITS─SPECT AND PET RADIOPHARMACEUTICALS

COMPANY PROFILES INCLUDE

AECL (Atomic Energy of Canada Ltd.)

ALGETA ASA (Norway)

ALPHAMED, INC.

ALSERAS PHARMACEUTICALS MOLECULAR IMAGING

AMERICAN RUSSIAN CANCER ALLIANCE (ARCA)

AMIC (American Medical Isotope Corp.)

ANSTO (Australian Nuclear Science and Technology Organization)

APOSENSE, LTD. (ISRAEL)

AVID RADIOPHARMACEUTICALS INC.

BIO-NUCLEONICS, INC.

BRACCO DIAGNOSTICS

CARDINAL HEALTH

CELLECTAR, LLC

COVIDIEN, INC.

CYTOGEN CORPORATION

DOW CHEMICAL CO.

DRAXIMAGE, INC.

GE HEALTHCARE

IBA MOLECULAR

IMMUNOMEDICS, INC.

LANTHEUS MEDICAL IMAGING INC

MDS NORDION

MOLECULAR INSIGHT PHARMACEUTICALS INC.

NTP RADIOISOTOPES (PTY) LTD (NTP) (South Africa)

P.E.T.NET SOLUTIONS

PHARMALUCENCE, INC.

ORDER FORM

Report No. 310 – US MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS

The report is priced at $9,500 plus $4,500 for a multi-user license.

Electronic PDF copies are available at no extra cost..

Please make check payable to: BIO-TECH SYSTEMS, INC.

For wire transfer, make deposit to:

BANK OF AMERICA, NEVADA
Post Office Box 98600
Las Vegas, Nevada 89193-8600
Routing/ABA #122 400 724

For credit to: BIO-TECH SYSTEMS, INC.
Account No. 501 282 7292

Mailing Information

Name:______________________________Title:_____________________________________

Company:____

Address____

City:_______________________State________Zip Code__________Country_____________

Telephone_______________________________FAX__________________________________

E-Mail____

P.O. #:_____________________________Signature_________________________________

Credit Cards: VISA, MC, AMEX, DISCOVER (Check One)

Credit Card No.____

Expiration: Month_______Year_____Name on Card :_________________________________

Signature____

Address for Credit Card Statements____

____

Return to:

BIO-TECH SYSTEMS, INC.
4167 W. Pinecrest Circle
Las Vegas, Nevada 89121
Telephone: (702) 456-7608 FAX (702) 456-2189
E-Mail: mburns@biotechsystems.com